<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="10918">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616421</url>
  </required_header>
  <id_info>
    <org_study_id>V59P20</org_study_id>
    <secondary_id>11278</secondary_id>
    <nct_id>NCT00616421</nct_id>
  </id_info>
  <brief_title>Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children</brief_title>
  <official_title>A Phase 3, Randomized, Observer-blind, Multi-Center Study to Compare the Safety and Immunogenicity of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With One Dose of Licensed Meningococcal ACWY Conjugate Vaccine Administered to Healthy Children 2-10 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and immune response of Novartis MenACWY conjugate vaccine when given
      to healthy children compared to a licensed Meningococcal ACWY polysaccharide-protein
      conjugate vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 5 Years of Age</measure>
    <time_frame>1 month postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percentages of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects With hSBA Seroresponse, in Healthy Children 6 to 10 Years of Age.</measure>
    <time_frame>1 month postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percenatages of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 10 Years of Age.</measure>
    <time_frame>1 month postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percentages of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA ≥ 1:8, in Healthy Children 2 to 10 Years of Age</measure>
    <time_frame>1 month postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percentages of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (hSBA), in Healthy Children 2 to 10 Years of Age.</measure>
    <time_frame>1 month postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with hSBA (human Serum Bactericidal Activity) Geometric Mean Titers (GMTs) response against N. meningitidis serogroups A, C, W-135, and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA ≥ 1:8, in Healthy Children 2 to 5 and 6 to 10 Years of Age.</measure>
    <time_frame>1 month postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percenategs of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (hSBA), in Healthy Children 2 to 5 and 6 to 10 Years of Age.</measure>
    <time_frame>1 month postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity of a single dose of the Novartis MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with hSBA (human Serum Bacterial Activity) Geometric Mean Titers (GMTs) response against N. meningitidis serogroups A, C, W-135, and Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 5 Years of Age (2 Doses vs 1 Dose)</measure>
    <time_frame>1 month postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity of two doses of the Novartis MenACWY-CRM, administered 2 months apart, is compared with the immunogenicity of a single dose of the Novartis MenACWY-CRM, directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With hSBA ≥ 1:8, in Healthy Children 2 to 5 Years of Age (2 Doses v/s 1 Dose)</measure>
    <time_frame>1 month postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity of two doses of the Novartis MenACWY-CRM, administered 2 months apart, is compared with the immunogenicity of a single dose of the Novartis MenACWY-CRM, directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMTs (hSBA) in Healthy Children 2 to 5 Years of Age (2 Doses v/s 1 Dose)</measure>
    <time_frame>1 month postvaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>The immunogenicity of two doses of the Novartis MenACWY-CRM vaccine, administered 2 months apart, is compared with the immunogenicity of a single dose of the Novartis MenACWY-CRM vaccine, in terms of hSBA (human Serum Bactericidal Activity) GMTs (Geometric Mean Titers) against N. meningitidis serogroups A, C, W-135, and Y.
ANOVA model used for the analysis of this outcome is different compare to ANOVA model used for the other outcome. The computed model components vary according to the variance observed due to the different datasets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With at Least One Reactogenicity Sign After Vaccination in Children 2 to 5 Years of Age - 1 Dose Vaccine Treatment.</measure>
    <time_frame>Study days 1 to 7</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety was assessed in terms of the percentages of subjects with reported local and systemic reactions up to 7 days after each vaccination per vaccination group, after 1 dose treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With at Least One Reactogenicity Sign After Vaccination in Children 6 to 10 Years of Age - 1 Dose Vaccine Treatment.</measure>
    <time_frame>Study days 1 to 7</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety was assessed in terms of the percentages of subjects with reported local and systemic reactions up to 7 days after each vaccination per vaccination group after 1 dose treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Unsolicited AEs Occurring Throughout the Study in Children Aged 2 to 10 Years - 1 Dose Vaccine Treatment.</measure>
    <time_frame>day 1 to study termination (day 240)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety was assessed in terms of the percentage of subjects with unsolicited AEs occurring throughout the entire study period, after 1 dose treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2907</enrollment>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>MenACWY-CRM (1 dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Licensed polysaccharide vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 injection of a licensed meningococcal MenACWY polysaccharide-protein conjugate vaccine administered by intramuscular (IM) injection on study day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY-CRM (2 doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) conjugate vaccine administered by intramuscular (IM) injection on study days 1 and 61.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM</intervention_name>
    <description>1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly</description>
    <arm_group_label>MenACWY-CRM (1 dose)</arm_group_label>
    <other_name>Menveo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM</intervention_name>
    <description>2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age</description>
    <arm_group_label>MenACWY-CRM (2 doses)</arm_group_label>
    <other_name>Menveo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Licensed meningococcal ACWY vaccine</intervention_name>
    <description>1 injection of the licensed meningococcal ACWY was administered intramuscularly</description>
    <arm_group_label>Licensed polysaccharide vaccine</arm_group_label>
    <other_name>Menactra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy 2-10 years of age children, inclusive and for whom, after the nature of the
             study has been explained, the parent or legal guardian has provided written informed
             consent

          -  who are available for all visits and telephone calls scheduled for the study

          -  who are up-to-date with age-appropriate routine childhood vaccinations

        Exclusion Criteria:

          -  whose parent or legal guardian is unwilling or unable to give written informed
             consent

          -  who had a previous or suspected disease caused by N. meningitidis;

          -  who have previously been immunized with a meningococcal vaccine or vaccine containing
             meningococcal antigen(s)

          -  who have received any investigational agents or vaccines within 90 days prior to
             enrollment

          -  who have any serious acute, chronic or progressive disease

          -  who have epilepsy or any progressive neurological disease or history of Guillain
             Barré Syndrome

          -  who have a history of anaphylaxis, serious vaccine reactions

          -  who have a known or suspected impairment/alteration of immune function, either
             congenital or acquired or resulting from

          -  who are known to have a bleeding diathesis, or any condition that may be associated
             with a prolonged bleeding time

          -  who have Down's syndrome or other known cytogenic disorders
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines and Diagnostics</last_name>
    <role>Study Director</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Investigational Reserach Program</name>
      <address>
        <city>Bentonville</city>
        <state>Arkansas</state>
        <zip>72712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Pediatric Research Group</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Health Research Center</name>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Fremont</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Hayward</name>
      <address>
        <city>Hayward</city>
        <state>California</state>
        <zip>94545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Pleasanton</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Jose</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Allergy &amp; Clinical Research</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longmont Medical Research Network</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Allergy &amp; Clinical Research</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Westminister</name>
      <address>
        <city>Westminister</city>
        <state>Colorado</state>
        <zip>80234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric Research Center</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians to Children &amp; Adolescents</name>
      <address>
        <city>Springfield</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Legacy Pediatrics</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham Pediatrics</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Pediatric Associates PA</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odyssey Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Senders and Associates</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Calcagno Research &amp; Development</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Health Care - West</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Pittsburgh Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>Pennsylvania</state>
        <zip>16125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Healthcare Partners</name>
      <address>
        <city>Grove City</city>
        <state>Pennsylvania</state>
        <zip>16127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates of Latrobe</name>
      <address>
        <city>Latrobe</city>
        <state>Pennsylvania</state>
        <zip>15650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Alliance PC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Alliance PC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Hills Pediatrics</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Alliance PC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Physicians Research Inc.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Physicians Research Inc.</name>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laurel Pediatrics</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Practice Medical Associates South</name>
      <address>
        <city>Upper St. Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Community Pediatrics</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Clinic Professional Association</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research Ft. Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research San Angelo</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wee Care Pediatrics</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cottonwood Pediatrics</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copperview Medical Center</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockwood Clinic</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockwood Clinic North</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TASC Research Services Inc.</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 8P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research Center</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colchester Regional Hospital</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albion Finch Medical Centre</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Western Ontario</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 1V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKDS Research In.</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herridge Community Health Clinic</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1S 0G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarnia Institute of Clinical Research</name>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicor Research Inc.</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Resolve Research Solutions</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Resolve Research Solutions</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5M 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <zip>C1A 8T5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Medical Clinic</name>
      <address>
        <city>Mount Pearl</city>
        <zip>A1N 1W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>White Hills Medical Clinic</name>
      <address>
        <city>Saint John's</city>
        <zip>A1A 3R5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Halperin SA, Gupta A, Jeanfreau R, Klein NP, Reisinger K, Walter E, Bedell L, Gill C, Dull PM. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine. 2010 Nov 23;28(50):7865-72. doi: 10.1016/j.vaccine.2010.09.092. Epub 2010 Oct 29.</citation>
    <PMID>20943209</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 19, 2016</lastchanged_date>
  <firstreceived_date>January 31, 2008</firstreceived_date>
  <firstreceived_results_date>February 28, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>children</keyword>
  <keyword>healthy</keyword>
  <keyword>meningitis</keyword>
  <keyword>meningococcal</keyword>
  <keyword>prevention of meningococcal disease serogroups ACWY</keyword>
  <keyword>Menveo</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lactitol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 67 centers in the USA and Canada.</recruitment_details>
      <pre_assignment_details>All subjects enrolled were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenACWY-CRM (2 Doses)</title>
          <description>2 injections of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) vaccine administered by intramuscular (IM) injection on study days 1 and 61 in children 2 to 5 years of age</description>
        </group>
        <group group_id="P2">
          <title>MenACWY-CRM (1 Dose)</title>
          <description>1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) vaccine administered by intramuscular (IM) injection on study day 1</description>
        </group>
        <group group_id="P3">
          <title>Licensed Polysaccharide Vaccine</title>
          <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered on study day 1</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="359"/>
                <participants group_id="P2" count="1278"/>
                <participants group_id="P3" count="1270"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="333"/>
                <participants group_id="P2" count="1240"/>
                <participants group_id="P3" count="1229"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inappropriate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to classify</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MenACWY-CRM (2 Doses)</title>
          <description>2 injections of the Novartis MenACWY-CRM vaccine administered on study days 1 and 61 in children 2 to 5 years of age.</description>
        </group>
        <group group_id="B2">
          <title>MenACWY-CRM (1 Dose)</title>
          <description>1 injection of the Novartis MenACWY-CRM (a nontoxic mutant of diptheria toxin) vaccine administered by intramuscular (IM) injection on study day1.</description>
        </group>
        <group group_id="B3">
          <title>Licensed Polysaccharide Vaccine</title>
          <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered on study day 1.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="359"/>
                <measurement group_id="B2" value="1278"/>
                <measurement group_id="B3" value="1270"/>
                <measurement group_id="B4" value="2907"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="3.5" spread="1.1"/>
                <measurement group_id="B2" value="5.5" spread="2.5"/>
                <measurement group_id="B3" value="5.6" spread="2.6"/>
                <measurement group_id="B4" value="5.3" spread="2.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="171"/>
                <measurement group_id="B2" value="622"/>
                <measurement group_id="B3" value="580"/>
                <measurement group_id="B4" value="1373"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="188"/>
                <measurement group_id="B2" value="656"/>
                <measurement group_id="B3" value="690"/>
                <measurement group_id="B4" value="1534"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 5 Years of Age</title>
        <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percentages of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
        <time_frame>1 month postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (1 Dose)</title>
            <description>1 injection of the Novartis MenACWY-CRM (a nontoxic diptheria toxin) vaccine administered on study day 1</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine</title>
            <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered on study day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="607"/>
                  <measurement group_id="O2" value="615"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 5 Years of Age</title>
            <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percentages of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Serogroup A (N=606, 611)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72" lower_limit="68" upper_limit="75"/>
                  <measurement group_id="O2" value="77" lower_limit="73" upper_limit="80"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C (N=607, 615)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60" lower_limit="56" upper_limit="64"/>
                  <measurement group_id="O2" value="56" lower_limit="52" upper_limit="60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W (N=594, 605)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72" lower_limit="68" upper_limit="75"/>
                  <measurement group_id="O2" value="58" lower_limit="54" upper_limit="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y (N=593, 600)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="66" lower_limit="62" upper_limit="70"/>
                  <measurement group_id="O2" value="45" lower_limit="41" upper_limit="49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 10 Years of Age.</title>
        <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percentages of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
        <time_frame>1 month postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (1 Dose)</title>
            <description>1 injection of the Novartis MenACWY-CRM (a nontoxic diptheria toxin) vaccine administered on study day 1</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine</title>
            <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered on study day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1161"/>
                  <measurement group_id="O2" value="1154"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 10 Years of Age.</title>
            <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percentages of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
            <units>Percenatage of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Serogroup A (N=1157, 1152)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="74" lower_limit="71" upper_limit="76"/>
                  <measurement group_id="O2" value="80" lower_limit="77" upper_limit="82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C (N=1161, 1154)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61" lower_limit="58" upper_limit="64"/>
                  <measurement group_id="O2" value="57" lower_limit="54" upper_limit="60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W (N=1136, 1138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65" lower_limit="62" upper_limit="67"/>
                  <measurement group_id="O2" value="51" lower_limit="48" upper_limit="54"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y (N=1138, 1139)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62" lower_limit="60" upper_limit="65"/>
                  <measurement group_id="O2" value="42" lower_limit="40" upper_limit="45"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With hSBA Seroresponse, in Healthy Children 6 to 10 Years of Age.</title>
        <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percenatages of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
        <time_frame>1 month postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (1 Dose)</title>
            <description>1 injection of the Novartis MenACWY-CRM (a nontoxic diptheria toxin) vaccine administered on study day 1</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine</title>
            <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered on study day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="554"/>
                  <measurement group_id="O2" value="541"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With hSBA Seroresponse, in Healthy Children 6 to 10 Years of Age.</title>
            <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percenatages of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Serogroup A (N=551, 541)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77" lower_limit="73" upper_limit="80"/>
                  <measurement group_id="O2" value="83" lower_limit="79" upper_limit="86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C (N=554, 539)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63" lower_limit="59" upper_limit="67"/>
                  <measurement group_id="O2" value="57" lower_limit="53" upper_limit="62"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W (N=542, 533)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57" lower_limit="53" upper_limit="61"/>
                  <measurement group_id="O2" value="44" lower_limit="40" upper_limit="49"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y (N=545, 539)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58" lower_limit="54" upper_limit="62"/>
                  <measurement group_id="O2" value="39" lower_limit="35" upper_limit="44"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA ≥ 1:8, in Healthy Children 2 to 10 Years of Age</title>
        <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percentages of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
        <time_frame>1 month postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (1 Dose)</title>
            <description>1 injection of the Novartis MenACWY-CRM (a nontoxic diptheria toxin) vaccine administered on study day 1</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine</title>
            <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered on study day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1161"/>
                  <measurement group_id="O2" value="1154"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With hSBA ≥ 1:8, in Healthy Children 2 to 10 Years of Age</title>
            <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percentages of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
            <units>Percentage of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Serogroup A (N=1157, 1152)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="75" lower_limit="72" upper_limit="77"/>
                  <measurement group_id="O2" value="80" lower_limit="78" upper_limit="83"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C (N=1161, 1154)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72" lower_limit="70" upper_limit="75"/>
                  <measurement group_id="O2" value="68" lower_limit="66" upper_limit="71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W (N=1136, 1138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90" lower_limit="88" upper_limit="92"/>
                  <measurement group_id="O2" value="60" lower_limit="57" upper_limit="63"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y (N=1138, 1139)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="77" lower_limit="75" upper_limit="80"/>
                  <measurement group_id="O2" value="79" lower_limit="77" upper_limit="81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (hSBA), in Healthy Children 2 to 10 Years of Age.</title>
        <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with hSBA (human Serum Bactericidal Activity) Geometric Mean Titers (GMTs) response against N. meningitidis serogroups A, C, W-135, and Y.</description>
        <time_frame>1 month postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (1 Dose)</title>
            <description>1 injection of the Novartis MenACWY-CRM (a nontoxic diptheria toxin) vaccine administered on study day 1</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine</title>
            <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered on study day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1161"/>
                  <measurement group_id="O2" value="1154"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (hSBA), in Healthy Children 2 to 10 Years of Age.</title>
            <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with hSBA (human Serum Bactericidal Activity) Geometric Mean Titers (GMTs) response against N. meningitidis serogroups A, C, W-135, and Y.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Serogroup A (N=1157, 1152)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="30" lower_limit="27" upper_limit="31"/>
                  <measurement group_id="O2" value="29" lower_limit="26" upper_limit="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C (N=1161, 1154)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23" lower_limit="21" upper_limit="27"/>
                  <measurement group_id="O2" value="17" lower_limit="15" upper_limit="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W (N=1136, 1138)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49" lower_limit="44" upper_limit="54"/>
                  <measurement group_id="O2" value="26" lower_limit="23" upper_limit="29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y (N=1138, 1139)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29" lower_limit="25" upper_limit="32"/>
                  <measurement group_id="O2" value="12" lower_limit="11" upper_limit="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA ≥ 1:8, in Healthy Children 2 to 5 and 6 to 10 Years of Age.</title>
        <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percenategs of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.</description>
        <time_frame>1 month postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2 to 5 Yoa)</title>
            <description>1 injection of the Novartis MenACWY-CRM vaccine administered by IM on study day 1 in children 2 to 5 years of age.</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine (2 to 5 Yoa)</title>
            <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered by IM on study day 1 in children 2 to 5 years of age.</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM (6 to 10 Yoa)</title>
            <description>1 injection of the Novartis MenACWY-CRM vaccine administered by IM on study day 1 in children 6 to 10 years of age.</description>
          </group>
          <group group_id="O4">
            <title>Licensed Polysaccharide Vaccine (6 to 10 Yoa)</title>
            <description>1 injection of the licensed meningococcal ACWY polysaccharide-protein conjugate administered by IM on study day 1 in children 6 to 10 years of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="607"/>
                  <measurement group_id="O2" value="554"/>
                  <measurement group_id="O3" value="615"/>
                  <measurement group_id="O4" value="541"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With hSBA ≥ 1:8, in Healthy Children 2 to 5 and 6 to 10 Years of Age.</title>
            <description>The immunogenicity of a single dose of MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the percenategs of subjects with seroresponse directed against N. meningitidis serogroups A, C, W-135, and Y.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Serogroup A (N=606, 611, 551, 541)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72" lower_limit="68" upper_limit="75"/>
                  <measurement group_id="O2" value="78" lower_limit="74" upper_limit="81"/>
                  <measurement group_id="O3" value="77" lower_limit="74" upper_limit="81"/>
                  <measurement group_id="O4" value="83" lower_limit="80" upper_limit="86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C (N=607, 615, 554, 539)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="68" lower_limit="64" upper_limit="72"/>
                  <measurement group_id="O2" value="64" lower_limit="60" upper_limit="68"/>
                  <measurement group_id="O3" value="77" lower_limit="73" upper_limit="89"/>
                  <measurement group_id="O4" value="74" lower_limit="70" upper_limit="77"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W (N=594, 605, 542, 533)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="90" lower_limit="87" upper_limit="92"/>
                  <measurement group_id="O2" value="75" lower_limit="71" upper_limit="78"/>
                  <measurement group_id="O3" value="91" lower_limit="88" upper_limit="93"/>
                  <measurement group_id="O4" value="84" lower_limit="81" upper_limit="87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y (N=593, 600, 545, 539)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76" lower_limit="72" upper_limit="79"/>
                  <measurement group_id="O2" value="57" lower_limit="53" upper_limit="61"/>
                  <measurement group_id="O3" value="79" lower_limit="76" upper_limit="83"/>
                  <measurement group_id="O4" value="63" lower_limit="59" upper_limit="67"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (hSBA), in Healthy Children 2 to 5 and 6 to 10 Years of Age.</title>
        <description>The immunogenicity of a single dose of the Novartis MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with hSBA (human Serum Bacterial Activity) Geometric Mean Titers (GMTs) response against N. meningitidis serogroups A, C, W-135, and Y.</description>
        <time_frame>1 month postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2 to 5 Yoa)</title>
            <description>1 injection of the Novartis MenACWY-CRM vaccine administered by IM on study day 1 in children 2 to 5 years of age.</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine (2 to 5 Yoa)</title>
            <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered by IM on study day 1 in children 2 to 5 years of age</description>
          </group>
          <group group_id="O3">
            <title>MenACWY-CRM (6 to 10 Yoa)</title>
            <description>1 injection of the Novartis MenACWY-CRM vaccine administered by IM on study day 1 in children 6 to 10 years of age.</description>
          </group>
          <group group_id="O4">
            <title>Licensed Polysaccharide Vaccine (6 to 10 Yoa)</title>
            <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered by IM on study day 1 in children 6 to 10 years of age</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="607"/>
                  <measurement group_id="O2" value="615"/>
                  <measurement group_id="O3" value="551"/>
                  <measurement group_id="O4" value="541"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Geometric Mean Titers (hSBA), in Healthy Children 2 to 5 and 6 to 10 Years of Age.</title>
            <description>The immunogenicity of a single dose of the Novartis MenACWY-CRM is compared with the immunogenicity of a single dose of the licensed ACWY polysaccharide vaccine, in terms of the number of subjects with hSBA (human Serum Bacterial Activity) Geometric Mean Titers (GMTs) response against N. meningitidis serogroups A, C, W-135, and Y.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Serogroup A (N=606, 611, 551, 541)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26" lower_limit="22" upper_limit="30"/>
                  <measurement group_id="O2" value="25" lower_limit="21" upper_limit="29"/>
                  <measurement group_id="O3" value="35" lower_limit="29" upper_limit="42"/>
                  <measurement group_id="O4" value="35" lower_limit="29" upper_limit="41"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C (N=607, 615, 554, 539)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18" lower_limit="15" upper_limit="20"/>
                  <measurement group_id="O2" value="13" lower_limit="11" upper_limit="15"/>
                  <measurement group_id="O3" value="36" lower_limit="29" upper_limit="42"/>
                  <measurement group_id="O4" value="27" lower_limit="21" upper_limit="33"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W (N=594, 605, 542, 533)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43" lower_limit="38" upper_limit="50"/>
                  <measurement group_id="O2" value="21" lower_limit="19" upper_limit="25"/>
                  <measurement group_id="O3" value="61" lower_limit="52" upper_limit="72"/>
                  <measurement group_id="O4" value="35" lower_limit="30" upper_limit="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y (N=593, 600, 545, 539)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="24" lower_limit="20" upper_limit="28"/>
                  <measurement group_id="O2" value="10" lower_limit="8.68" upper_limit="12"/>
                  <measurement group_id="O3" value="34" lower_limit="28" upper_limit="41"/>
                  <measurement group_id="O4" value="14" lower_limit="12" upper_limit="17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 5 Years of Age (2 Doses vs 1 Dose)</title>
        <description>The immunogenicity of two doses of the Novartis MenACWY-CRM, administered 2 months apart, is compared with the immunogenicity of a single dose of the Novartis MenACWY-CRM, directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
        <time_frame>1 month postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2 Doses)</title>
            <description>2 injections of the Novartis MenACWY-CRM vaccine administered by IM on study days 1 and 61 in children 2 to 5 years of age</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM (1 Dose)</title>
            <description>1 injection of the Novartis MenACWY-CRM vaccine administered by IM on study day 1 in children 2 to 5 years of age</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="293"/>
                  <measurement group_id="O2" value="607"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With hSBA Seroresponse, in Healthy Children 2 to 5 Years of Age (2 Doses vs 1 Dose)</title>
            <description>The immunogenicity of two doses of the Novartis MenACWY-CRM, administered 2 months apart, is compared with the immunogenicity of a single dose of the Novartis MenACWY-CRM, directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Serogroup A (N=291, 606)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91" lower_limit="87" upper_limit="94"/>
                  <measurement group_id="O2" value="72" lower_limit="68" upper_limit="75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C (N=293, 607)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98" lower_limit="95" upper_limit="99"/>
                  <measurement group_id="O2" value="60" lower_limit="56" upper_limit="64"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W (N=288, 594)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89" lower_limit="85" upper_limit="92"/>
                  <measurement group_id="O2" value="72" lower_limit="68" upper_limit="75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y (N=286, 593)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95" lower_limit="91" upper_limit="97"/>
                  <measurement group_id="O2" value="66" lower_limit="62" upper_limit="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With hSBA ≥ 1:8, in Healthy Children 2 to 5 Years of Age (2 Doses v/s 1 Dose)</title>
        <description>The immunogenicity of two doses of the Novartis MenACWY-CRM, administered 2 months apart, is compared with the immunogenicity of a single dose of the Novartis MenACWY-CRM, directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
        <time_frame>1 month postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2 Doses)</title>
            <description>2 injections of the Novartis MenACWY-CRM vaccine administered by IM on study days 1 and 61 in children 2 to 5 years of age</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM (1 Dose)</title>
            <description>1 injection of the Novartis MenACWY-CRM vaccine administered by IM on study day 1 in children 2 to 5 years of age</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="293"/>
                  <measurement group_id="O2" value="607"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With hSBA ≥ 1:8, in Healthy Children 2 to 5 Years of Age (2 Doses v/s 1 Dose)</title>
            <description>The immunogenicity of two doses of the Novartis MenACWY-CRM, administered 2 months apart, is compared with the immunogenicity of a single dose of the Novartis MenACWY-CRM, directed against N. meningitidis serogroups A, C, W-135, and Y.
Seroresponse: For a subject with hSBA &lt;1:4 at baseline, seroresponse is defined as a postvaccination hSBA ≥ 1:8; for a subject with hSBA ≥ 1:4 at baseline, seroresponse is defined as a postvaccination hSBA titer of at least 4 times the baseline.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Serogroup A (N=291, 606)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="91" lower_limit="88" upper_limit="94"/>
                  <measurement group_id="O2" value="72" lower_limit="68" upper_limit="75"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C (N=293, 607)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                  <measurement group_id="O2" value="68" lower_limit="64" upper_limit="72"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W (N=288, 594)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99" lower_limit="98" upper_limit="100"/>
                  <measurement group_id="O2" value="90" lower_limit="87" upper_limit="92"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y (N=286, 593)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98" lower_limit="95" upper_limit="99"/>
                  <measurement group_id="O2" value="76" lower_limit="72" upper_limit="79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMTs (hSBA) in Healthy Children 2 to 5 Years of Age (2 Doses v/s 1 Dose)</title>
        <description>The immunogenicity of two doses of the Novartis MenACWY-CRM vaccine, administered 2 months apart, is compared with the immunogenicity of a single dose of the Novartis MenACWY-CRM vaccine, in terms of hSBA (human Serum Bactericidal Activity) GMTs (Geometric Mean Titers) against N. meningitidis serogroups A, C, W-135, and Y.
ANOVA model used for the analysis of this outcome is different compare to ANOVA model used for the other outcome. The computed model components vary according to the variance observed due to the different datasets.</description>
        <time_frame>1 month postvaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>The analysis was performed on the per-protocol (PP) population.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (2 Doses)</title>
            <description>2 injections of the Novartis MenACWY-CRM vaccine administered by IM on study days 1 and 61 in children 2 to 5 years of age</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM (1 Dose)</title>
            <description>1 injection of the Novartis MenACWY-CRM vaccine administered by IM on study day 1 in children 2 to 5 years of age</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="293"/>
                  <measurement group_id="O2" value="607"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>GMTs (hSBA) in Healthy Children 2 to 5 Years of Age (2 Doses v/s 1 Dose)</title>
            <description>The immunogenicity of two doses of the Novartis MenACWY-CRM vaccine, administered 2 months apart, is compared with the immunogenicity of a single dose of the Novartis MenACWY-CRM vaccine, in terms of hSBA (human Serum Bactericidal Activity) GMTs (Geometric Mean Titers) against N. meningitidis serogroups A, C, W-135, and Y.
ANOVA model used for the analysis of this outcome is different compare to ANOVA model used for the other outcome. The computed model components vary according to the variance observed due to the different datasets.</description>
            <units>Titers</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Serogroup A (N=291, 606)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64" lower_limit="51" upper_limit="81"/>
                  <measurement group_id="O2" value="27" lower_limit="23" upper_limit="82"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup C (N=293, 607)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="144" lower_limit="118" upper_limit="177"/>
                  <measurement group_id="O2" value="18" lower_limit="15" upper_limit="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup W (N=288, 594)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="132" lower_limit="111" upper_limit="157"/>
                  <measurement group_id="O2" value="41" lower_limit="36" upper_limit="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Serogroup Y (N=286, 593)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="102" lower_limit="82" upper_limit="126"/>
                  <measurement group_id="O2" value="23" lower_limit="20" upper_limit="27"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With at Least One Reactogenicity Sign After Vaccination in Children 2 to 5 Years of Age - 1 Dose Vaccine Treatment.</title>
        <description>Safety was assessed in terms of the percentages of subjects with reported local and systemic reactions up to 7 days after each vaccination per vaccination group, after 1 dose treatment.</description>
        <time_frame>Study days 1 to 7</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis was performed on the safety population. Only groups receiving 1 dose vaccine are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (1 Dose)</title>
            <description>The Novartis MenACWY-CRM vaccine was administered by IM in children 2 to 5 years of age.</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine (1 Dose)</title>
            <description>The licensed meningococcal MenACWY polysaccharide vaccine was administered by IM in children 2 to 5 years of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="693"/>
                  <measurement group_id="O2" value="684"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With at Least One Reactogenicity Sign After Vaccination in Children 2 to 5 Years of Age - 1 Dose Vaccine Treatment.</title>
            <description>Safety was assessed in terms of the percentages of subjects with reported local and systemic reactions up to 7 days after each vaccination per vaccination group, after 1 dose treatment.</description>
            <units>Percentages of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Injection site pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change in Eating Habits (N=683, 671)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Sleepiness (N=692, 684)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Irritability (N=692, 684)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Vomiting (N=692, 684)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Diarrhea (N=692, 684)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever ( ≥ 38C ; N=692, 684)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever ( ≥ 40.0C )</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stayed home (N=682, 670)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Analgesic/Antipyretic medication used</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With at Least One Reactogenicity Sign After Vaccination in Children 6 to 10 Years of Age - 1 Dose Vaccine Treatment.</title>
        <description>Safety was assessed in terms of the percentages of subjects with reported local and systemic reactions up to 7 days after each vaccination per vaccination group after 1 dose treatment.</description>
        <time_frame>Study days 1 to 7</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis was performed on the safety population. Only groups receiving 1 dose vaccine are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (1 Dose)</title>
            <description>The Novartis MenACWY-CRM vaccine was administered by IM in children 6 to 10 years of age.</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine (1 Dose)</title>
            <description>The licensed meningococcal MenACWY polysaccharide vaccine was administered by IM in children 6 to 10 years of age.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="582"/>
                  <measurement group_id="O2" value="571"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With at Least One Reactogenicity Sign After Vaccination in Children 6 to 10 Years of Age - 1 Dose Vaccine Treatment.</title>
            <description>Safety was assessed in terms of the percentages of subjects with reported local and systemic reactions up to 7 days after each vaccination per vaccination group after 1 dose treatment.</description>
            <units>Percenatage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Injection site pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Injection site induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Chills</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Nausea</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Myalgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Arthralgia</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Rash</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever ( ≥ 38C ; N=582, 570)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever ( ≥ 40.0C ; N=582, 570)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Stayed home (N=575, 566)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Analgesic/Antipyretic medication used</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Unsolicited AEs Occurring Throughout the Study in Children Aged 2 to 10 Years - 1 Dose Vaccine Treatment.</title>
        <description>Safety was assessed in terms of the percentage of subjects with unsolicited AEs occurring throughout the entire study period, after 1 dose treatment.</description>
        <time_frame>day 1 to study termination (day 240)</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The analysis was performed on safety population. Only groups receiving 1 dose vaccine are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM (1 Dose)</title>
            <description>1 injection of the Novartis MenACWY-CRM (a nontoxic diptheria toxin) vaccine administered on study day 1</description>
          </group>
          <group group_id="O2">
            <title>Licensed Polysaccharide Vaccine (1 Dose)</title>
            <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered on study day 1</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1275"/>
                  <measurement group_id="O2" value="1255"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentages of Subjects With Unsolicited AEs Occurring Throughout the Study in Children Aged 2 to 10 Years - 1 Dose Vaccine Treatment.</title>
            <description>Safety was assessed in terms of the percentage of subjects with unsolicited AEs occurring throughout the entire study period, after 1 dose treatment.</description>
            <units>Percentage of Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Any AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Possibly probably related AEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>AEs leading to discontinuation</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Possibly probably related SAEs</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Death</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events and serious adverse events were collectedfrom day 1 to study terminaton (day 240).</time_frame>
      <desc>If the adverse event was solicited then the event is listed as systematic assessment. However, if the adverse event was not solicited (i.e., unsolicited), then the event is listed under non-systematic method of collection. Subjects not vaccinated were excluded from the safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>MenACWY-CRM (2 Doses)</title>
          <description>2 injections of the Novartis MenACWY-CRM vaccine administered by IM on study days 1 and 61 in children 2 to 5 years of age</description>
        </group>
        <group group_id="E2">
          <title>MenACWY-CRM (1 Dose)_2 to 5 Years</title>
          <description>1 injection of the Novartis MenACWY-CRM vaccine administered on study day 1 in children 2 to 5 years of age.</description>
        </group>
        <group group_id="E3">
          <title>MenACWY-CRM (1 Dose)_6 to 10 Years</title>
          <description>1 injection of the Novartis MenACWY-CRM vaccine administered on study day 1 in children 6 to 10 years of age.</description>
        </group>
        <group group_id="E4">
          <title>Licensed Polysaccharide Vaccine_2 to 5 Years</title>
          <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered on study day 1 in children 2 to 5 years of age.</description>
        </group>
        <group group_id="E5">
          <title>Licensed Polysaccharide Vaccine_6 to 10 Years</title>
          <description>1 injection of the licensed meningococcal MenACWY polysaccharide vaccine administered on study day 1 in children 6 to 10 years of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Mouth Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Parvovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Shigella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Cellulitis Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Adrenal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Skin Abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Pulmonary Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Traumatic Lung Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric Symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial Spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="253" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="424" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="340" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="419" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="342" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="37" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="151" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="226" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="241" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="256" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="131" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="186" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="164" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="170" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="126" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>irritablility</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="152" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="97" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="126" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="73" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>mailaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="82" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="62" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="59" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>somnolence</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="126" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="79" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="351"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="693"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="582"/>
                <counts group_id="E4" subjects_affected="69" subjects_at_risk="684"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="571"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@Novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
